Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer
2025-10-01
|
| シリーズ: | Discover Oncology |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1007/s12672-025-03569-x |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|